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Prostate Cancer Biochemical Recurrence Rates After
Robotic-Assisted Laparoscopic Radical Prostatectomy
Serge Ginzburg, MD, Thomas Nevers, MD, Ilene Staff, PhD, Joseph Tortora, MS,
Alison Champagne, BS, Stuart S. Kesler, MD, Vincent P. Laudone, MD, Joseph R. Wagner, MD
ABSTRACT
Background and Objectives: To determine prostate
cancer biochemical recurrence rates with respect to sur-
gical margin (SM) status for patients undergoing robotic-
assisted laparoscopic radical prostatectomy (RALP).
Methods: IRB-approved radical prostatectomy database
was queried. Patients were stratified as low, intermediate,
and high risk according to D’Amico’s risk classification.
Postoperative prostate-specific antigen (PSA) values were
obtained every 3 mo for the first year, then biannually and
annually thereafter. Biochemical recurrence was defined
as 0.2ng/mL. Patients receiving adjuvant or salvage
treatment were included. Positive surgical margin was
defined as presence of cancer cells at inked resection
margin in the final specimen. Margin presence (negative/
positive), margin multiplicity (single/multiple), and mar-
gin length (3mm focal and 3mm extensive) were
noted. Kaplan-Meier curves of biochemical recurrence-
free survival (BRFS) as a function of SM were generated.
Forward stepwise multivariate Cox regression was per-
formed, with preoperative PSA, Gleason score, pathologic
stage, prostate gland weight, and SM as covariates.
Results: At our institution, 1437 patients underwent RALP
(2003-2009). Of these, 1159 had sufficient data and were
included in our analysis. Mean follow-up was 16 mo.
Kaplan-Meier curves demonstrated significant increase in
BRFS in low-risk and intermediate-risk groups with neg-
ative SM. Overall BRFS at 5 y was 72%. Gleason score,
pathologic stage, and SM status were significant prognos-
tic factors in multivariate analysis.
Conclusions: Negative surgical margins resulted in lower
biochemical recurrence rates for low-risk and intermedi-
ate-risk groups. Multifocal and longer positive margins
were associated with higher biochemical recurrence rates
compared with unifocal and shorter positive margins.
Documenting biochemical recurrence rates for RALP is
important, because this treatment for localized prostate
cancer is validated.
Key Words: Prostate cancer, PSA, Recurrence, Robotic
surgery.
INTRODUCTION
Robotic-assisted laparoscopic radical prostatectomy (RALP)
has gained popularity around the world. This year the
number of robotic cases again exceeds that of traditional
open prostatectomy cases in the United States, with 85%
performed robotically.1 We performed a review of our
prostate cancer database to demonstrate trends in bio-
chemical recurrence (BCR) in a large cohort of patients
undergoing RALP, as a function of preoperative prostate-
specific antigen (PSA) levels, Gleason score, TNM stage,
and surgical margins (SM). Our primary objective was to
determine prostate cancer BCR rates with respect to SM
status for patients undergoing RALP. We also compared
our BCR rates to other open and laparoscopic radical
prostatectomy series reported in the literature.
MATERIALS AND METHODS
A retrospective review of a prospectively maintained, In-
ternal Review Board (IRB)-approved radical prostatec-
tomy database was performed. Patients undergoing RALP
between December 1, 2003 and January 1, 2009 were
eligible for analysis.
All RALP procedures were performed via a transperitoneal
approach by 1 of 3 surgeons using a modified Vattikuti
Institute technique.2 DaVinci, DaVinci S, and DaVinci S
HD Surgical Systems (Intuitive Surgical, Sunnyvale, CA,
USA) were used to perform the procedures. Learning
curves when present for all surgeons were included.
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SCIENTIFIC PAPER
The demographic information, clinical staging, and intra-
operative details were prospectively collected and entered
into the database. Using preoperative data, patients were
stratified as low, intermediate, and high risk according to
D’Amico’s risk classification.3 Specifically, the low-risk
group was defined as having serum PSA10ng/mL, Glea-
son score7, and clinical stagecT2b. The intermediate-
risk group was defined as having serum PSA between
10ng/mL and 20ng/mL or Gleason score equal to 7. The
high-risk group was defined as having serum PSA
20ng/mL or Gleason score 8 to 10.
Surgical margin status was determined by pathologic eval-
uation of the specimen at a single institution. AJCC 2002
staging guidelines were consistently used by the pathol-
ogists.4 All specimens were whole-mounted and step-
sectioned at 3-mm intervals with apex and base being
additionally cross-sectioned. Positive surgical margin was
defined as the presence of cancer cells at the inked resec-
tion margin in the final specimen. Intraoperative biopsy
results or additional tissue excisions were not used to
determine margin positivity. Margin presence (negative/
positive), margin multiplicity (single/multiple), and mar-
gin length (3mm focal and 3mm extensive) were
noted.
Postoperative PSA values were routinely obtained at 1, 3,
6, 9, 12, 18, and 24 mo and annually thereafter. PSA
recurrence was defined as 0.2ng/mL. Patients receiving
adjuvant treatment were included in our analyses and
were considered as having recurred at the time of adju-
vant treatment.
We excluded 278 patients due to lack of postoperative
PSA or lack of follow-up at our institution. Demographic
comparison was performed between excluded and in-
cluded patients.
Data were extracted from the prostate database and en-
tered into SPSS v 14.0 statistical software (SPSS, Inc., Chi-
cago, IL, USA.) Univariate analysis was performed for the
overall cohort, as well as for patients stratified by Gleason
score, TNM stage, and D’Amico classification, comparing
biochemical recurrence-free survival (BRFS) with respect
to SM status. BRFS was defined as time from RALP to BCR.
Patients without BCR were censored on the date of their
last PSA measurement. Kaplan-Meier plots of BRFS were
generated for the above categories. Differences relative to
SM status were evaluated using the log-rank test. Multi-
variate Cox regression analysis was also performed.
Pathologic stage (pT2N0M0, pT3aN0M0, pT3b/4N0M0,
pTxN1Mx), pathologic grade (pathologic Gleason score
6, 7, and 8 to 10), SM status (negative/positive), margin
multiplicity (single/multiple), and margin length (3mm
focal and 3mm extensive) were entered as categorical
variables with the first category as the reference group.
Preoperative PSA, transformed to its natural logarithm to
minimize effects of extreme values, an approach previ-
ously described in the literature, was entered as a contin-
uous variable.5 Statistical significance was set at 2-sided
P  .05.
To evaluate whether nerve-sparing status is a risk factor
for positive margins, a univariate analysis was performed
for bilateral, unilateral, and non–nerve-sparing proce-
dures. The impact of the learning curve on margin status
was examined by performing a univariate analysis on
each quartile of cases.
RESULTS
Between December 1, 2003 and January 2009, 1437 pa-
tients underwent RALP procedures performed by 3 sur-
geons at our institution. Of these, 278 patients were ex-
cluded due to lack of follow-up at our institution and lack
of postoperative PSA. Sixteen patients received adjuvant
therapy and were included in our analysis. Specifically, 9
patients underwent adjuvant radiation therapy, 3 received
adjuvant androgen deprivation therapy, and 4 received
both. A total of 1159 patients were included in our anal-
ysis.
Patient demographics are presented in Table 1. Mean age,
body mass index (BMI), and preoperative PSA values
were 59.3 y, 28.1kg/m2, and 5.9ng/mL, respectively. Pa-
tients had a mean follow-up of 15.9 mo (0 to 60). Predict-
ably, preoperative serum PSA demonstrated a statistically
significant difference between the 2 groups, with higher
values for those with positive surgical margins (P  .001).
The distribution of clinical Gleason score (P  .003),
D’Amico risk stratification (P  .001), pathological Gleason
(P  .001), and pathologic stage (P  .001) also demon-
strated a statistically significant difference. Patients with pos-
itive margins had higher stage, grade, and risk. Neither per-
formance of pelvic lymphadenectomy (P  .182) nor
presence of positive lymph nodes (P .139) was statistically
different between the 2 groups.
Excluded patients were compared with the analyzed pa-
tients and no statistically significant differences were
found in the demographic, operative, or pathologic char-
acteristics, with exception of frequency of pelvic lymph-
adenectomy. Pelvic lymphadenectomy was performed on
48.6% of excluded patients vs. 58.9% in the analyzed
population (P  .002).
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The frequency of positive margins in the overall cohort
was 27.3%, 20.3% for pathologic stage T2, and 52.3% for
pathologic stage T3a disease. Specifically, in patients
with Gleason score 6, pathologic stage T2N0M0 and
T3aN0M0 had 14.9% and 65% incidence of positive surgi-
cal margin (PSM), respectively. In patients with Gleason
Table 1.
Demographic Data
Negative Margin Positive Margin All Patients P Value
Number of patients (%) 843 (72.7%) 316 (27.3%) 1159 (100.0%)
Mean age, years (SDa) 59.3 (6.5) 59.2 (6.4) 59.3 (6.5) .987
Mean BMI, kg/m2 (SDa) 28.1 (7.2) 28.0 (3.9) 28.1 (6.4) .693
Mean preoperative PSAa, ng/mL (SDa) 5.4 (2.8) 7.4 (6.7) 5.9 (4.4) .001
Clinical Gleason score .003
6 485 (76.6%) 148 (23.4%) 633 (100.0%)
7 295 (68.6%) 135 (31.4%) 430 (100.0%)
8–10 61 (64.9%) 33 (35.1%) 94 (100.0%)
Clinical stage .073
cT1 588 (73.2%) 215 (26.8%) 803 (100.0%)
cT2 246 (72.8%) 92 (27.2%) 338 (100.0%)
cT3 7 (46.7%) 8 (53.3%) 15 (100.0%)
Risk class (D’Amico) .001
Low 439 (77.0%) 131 (23.0%) 570 (100.0%)
Intermediate 329 (71.4%) 132 (28.6%) 461 (100.0%)
High 74 (58.3%) 53 (41.7%) 127 (100.0%)
Pathologic Gleason score .001
6 294 (82.4%) 63 (17.6%) 357 (100.0%)
7 483 (69.1%) 216 (30.9%) 699 (100.0%)
8–10 60 (61.9%) 37 (38.1%) 97 (100.0%)
Pathologic stage .001
pT0–pT2N0M0 718 (79.9%) 183 (20.3%) 901 (100.0%)
T3aN0M0 89 (46.8%) 101 (53.2%) 190 (100.0%)
T3b and pT4N0M0 25 (50.0%) 25 (50.0%) 50 (100.0%)
TxN1Mx (positive nodes) 8 (53.3%) 7 (46.7%) 15 (100.0%)
Mean follow-up, months (SDa) 15.6 (13.0) 16.5 (14.3) 15.9(13.4) .337
Learning curve .248
First quartile 201 (69.3%) 89 (30.7%) 290 (100%)
Second quartile 217 (74.8%) 73 (25.2%) 290 (100%)
Third quartile 219 (75.8%) 70 24.2%) 289 (100%)
Fourth quartile 206 (71.0%) 84 (29.0%) 290 (100%)
Nerve sparing status .672
Bilateral nerve sparing 564 (72.7%) 212 (27.3%) 776 (100%)
Unilateral nerve sparing 217 (73.8%) 77 (26.2%) 294 (100%)
Non nerve sparing 60 (69.0%) 27 (31.0%) 87 (100%)
aSDstandard deviation; BMIbody mass index; PSAprostate-specific antigen.
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score 7, the incidence of PSM for stage T2N0M0,
T3aN0M0, T3b/T4N0M0, and TxN1Mx was 24.1%, 53.2%,
51.7%, and 12.5%, respectively. In patients with Gleason
score 8 to 10, the incidence of PSM for stage T2N0M0,
T3aN0M0, T3b/T4N0M0, and TxN1Mx was 17.9%, 45.2%,
50.0%, and 85.7%, respectively.
BRFS curves were generated for the overall cohort as well
as individual D’Amico risk groups and are depicted in
Figure 1. Low-risk and intermediate-risk groups achieved
a statistically significant difference in BRSF with respect to
SM. In the low-risk group, mean BRFS was 56.7 vs. 51.0
mo (P  .005), and in the intermediate-risk group it was
55.2 vs. 43.5 mo (P  .001) for negative and positive SM,
respectively. The high-risk group did not reach statistical
significance with respect to SM. The overall cohort mean
BRFS was statistically significant, 54.9 vs. 45.9 mo (P 
.001) for negative and positive SM, respectively.
Similar curves were generated for individual pathologic
tumor stage and pathologic Gleason score for positive and
negative SM and are depicted in Figure 2. Patients with
Gleason score of 7 and pathologic stage T2N0M0 had a
statistically significant difference in mean BRFS of 55.6 and
48.7 mo (P  .001) for negative and positive margins,
respectively. Others did not have a statistically significant
difference in BCRF survival with respect to SM.
When surgical margins were further categorized by mul-
tiplicity and length, multiple margins and extensive mar-
gins carried a higher rate of BCR (P  .001) (Figures 3
and 4). The rates of positive surgical margins did not
change significantly between quartile of cases (P  .243,
Table 1). Nerve-sparing surgical status did not significantly
affect the incidence of positive surgical margins (P .672,
Table 1).
The multivariate prediction of time to BRFS showed path-
ological stage (P  .001), pathologic Gleason grade (P 
.001), and SM (P  .035) as significant covariates. Data for
preoperative PSA was suggestive but missed statistical
significance (P  .053). While margin multiplicity and
margin length were significant in univariate analysis, they
were not in multivariate analysis. Hazard ratios (HR) and
confidence intervals (CI) for each variable in the equation
are listed in Table 2.
Figure 1. Biochemical recurrence-free survival for D’Amico risk groups and over all by surgical margin status.
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DISCUSSION
The importance of positive SM, its impact on BRFS, and as
a result, its impact on disease-specific survival has been
previously established in univariate and multivariate anal-
yses.6–8 In our series, the frequency of positive SM for the
overall cohort was slightly higher than but within the
range reported in the literature for both open and robotic
series.5,9–13 While some series have shown that margin
rates improve with surgical volume, this was not our
experience.5,14,15 Our margin rates were fairly constant
over the time period examined, most likely because 2 of
our 3 surgeons had gone through their learning curves
during fellowship and/or prior to joining our institu-
tion; the learning curve of only 1 surgeon is present in
our data.
Figure 2. Cumulative biochemical recurrence-free survival by Gleason score and pathologic stage.
Figure 3. Biochemical recurrence-free survival by margin
length.
Figure 4. Biochemical recurrence-free survival buy margin mul-
tiplicity.
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With respect to SM status, our analyses demonstrate that
the following groups reached statistically significant dif-
ference in BRFS: pT2/Gleason 7, D’Amico low-risk and
intermediate–risk groups, and the overall cohort. The rest
of the groups did not show a statistically significant dif-
ference for BCRF survival with respect to SM. One possi-
ble explanation is that these groups were underpowered.
Alternatively, the lack of statistical difference may be real
and represents the minimal impact of SM on BRFS in
certain subgroups. It is known that prostate cancer in
patients with Gleason score6 tends to not recur, regard-
less of SM status, as demonstrated by our pT2/Gleason
score 6 subgroup. This phenomenon is supported by a
recent publication by Caire et al.16 where authors con-
cluded that patients with pathologic Gleason score 7
had a significantly delayed BCR as compared with those
with Gleason score 7. These authors also found that
delayed BCR confers a disease-specific survival advan-
tage. Similarly, Karakiewicz et al.13 determined SM to be a
significant predictor of BCR only for Gleason score 7.
In the multivariate analysis, SM remained a significant
predictor of BCR, as did pathologic stage and Gleason
score. When positive margins were further categorized by
length and multiplicity, multiple positive margins and ex-
tensive positive margins carried a higher rate of BCR.
Preoperative PSA did not quite reach statistical signifi-
cance. Pavlovich et al.17 also failed to find significant
association between preoperative PSA levels and BCR.
Once pathologic stage, Gleason score, and margin status
were included in the analysis, the significance of preop-
erative PSA was lost. Although serum PSA level may play
a role in screening and as a tumor marker to detect BCR
postoperatively, the prognostic ability of preoperative se-
rum PSA with respect to BCR is not supported by our
analysis.
Our cumulative BRFS was 93.3%, 90.6%, 86.2%, 79.7%,
and 72.0% at 1, 2, 3, 4, and 5 y after RALP, respectively.
The 5-y BRFS of 72% is comparable to other series in the
literature. Murphy et al.15 reported 74.0% for robotic-as-
Table 2.
Multivariate analysis of biochemical recurrence-free survival
Variable HRc CIc (95%) P Value
Pathologic stage .001
pT2N0M0 1.0 (reference)
pT3aN0M0 2.30 1.34–3.97 .003
pT3b/T4N0M0 5.22 2.72–9.99 .001
pTxN1Mx 13.48 5.61–32.42 .001
Pathologic Gleason score .001
6 1.0 (reference)
7 3.42 1.34–8.75 .01
8–10 10.13 3.66–28.02 .001
Surgical margin statusa .035
Negative 1.0 (reference)
Positive 1.63 1.83–2.56 .035
Margin multiplicityb
Single 1.0 (reference)
Multiple .98 .48–2.01 .954
Margin lengthb
 3mm 1.0 (reference)
3mm 1.45 .74–2.87 .281
Preoperative PSAc 1.44 0.995–2.09 .053
a Comparing negative vs positive margin for all patients.
b Comparing length and multiplicity among those with positive margins.
cHRhazard ratio; CI  confidence interval); PSAprostate-specific antigen.
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sisted, Rassweiler et al.18 73.1% for laparoscopic, and
Karakiewicz et al.13 75.4% for open radical retropubic
prostatectomy series.
Sixteen patients in our study received adjuvant therapy
and were included in our analysis as failures whether PSA
nadired or not. Whether to include or exclude these pa-
tients is not well defined in the literature. Swindle et al.6
confirmed the persistent significance of positive surgical
margins on BRFS when patients receiving adjuvant ther-
apy were either considered to recur at the time of adjuvant
therapy or were excluded. Although our database con-
tains few patients receiving adjuvant therapy, when a
similar analysis was performed our outcomes did not
change significantly (results not shown).
We acknowledge that the retrospective nature of this
study may allow for selection bias. Although patients with
positive and negative margins differed in pathologic and
clinical characteristics, subgroup analyses by D’Amico
risk, TNM stage, and Gleason grade attempted to mini-
mize the above differences.
Patients who had insufficient clinical and pathological
data, who were lost to follow-up, or who chose to fol-
low-up elsewhere were not captured by this study, al-
though every effort was made to do so. Analysis of avail-
able data for 278 excluded patients compared with the
1159 included patients did not show any significant dif-
ference except for the frequency of pelvic lymph node
dissection, which was lower in the excluded group (48.6%
vs. 58.9%). Performance of lymph node dissection was at
the surgeon’s discretion, and lower frequency of lymph-
adenectomy in the excluded patients suggests that this
group was at a lower risk for nodal metastasis and recur-
rence. Thus, if these patients were included, resultant
BRFS would likely increase.
This study is also limited by the length of follow-up. Early
stage/low-grade prostate cancer is indolent and BCR may
not be captured within our follow-up interval, thus pos-
sibly minimizing the significance of SM. Because we are a
tertiary care center, most of our patients receive follow-up
care with their local urologists, and we are exploring other
avenues for data capture such as on-line surveys, auto-
mated calls, and other such things. Future studies with
longer follow-up would allow evaluation of more direct
metrics, such as disease-specific survival, metastasis-free
survival, and overall survival.
CONCLUSIONS
This study confirms the significance of SM on BRFS in a
large cohort of RALP patients. BCR rates for robotic, lapa-
roscopic, and open series appear to be comparable. Our
BRFS further validates a robotic-assisted approach for the
treatment of prostate cancer. Longer follow-up is needed
to better define the impact of margin status on BCR. A
multi-institutional approach would further strengthen the
role of RALP as comparable to radical retropubic prosta-
tectomy.
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